Juvenile Dermatomyositis: Advances in Basic Research, Translational Studies and Clinical care
This symposium, co-hosted by Duke University and Cure JM Foundation on March 12, 2022, provides important information on Juvenile Myositis research.
Biologics are a therapies that derived from living cells or through biological processes. They are a promising new class of drugs used to treat myositis.
Second-line treatments refer to options beyond steroids and methotrexate. They are designed to manage JM while reducing reliance on those medications. We understand that adding new treatments to your child’s regimen can be intimidating. However, rest assured that your doctor has carefully considered the benefits and risks of each option to design the best treatment plan for your family.
We are pleased to invite all juvenile dermatomyositis healthcare professionals to join us virtually for the latest presentations, sharing clinical best practices to help providers diagnose, treat, and care for juvenile myositis patients.
Membership is free and we’ll connect you with a network of support, encouragement, and resources.
To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.
